OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
Ticker SymbolOABIW
Company nameOmniAb Inc
IPO dateOct 09, 2020
CEOMr. Matthew William (Matt) Foehr
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address5980 Horton Street
CityEMERYVILLE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94608
Phone15102507800
Websitehttps://www.omniab.com/
Ticker SymbolOABIW
IPO dateOct 09, 2020
CEOMr. Matthew William (Matt) Foehr
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data